Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor

Liver International

Volumn 27, Issue 9, 2007, Pages 1282-1286

  Soejima, Yuji ^a   Shimada, Mitsuo ^b   Taketomi, Akinobu ^a   Yoshizumi, Tomoharu ^a   Uchiyama, Hideaki ^a   Ikegami, Toru ^a   Nakamuta, Makoto ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Adefovir dipivoxil; Hepatitis B surface antigen positive donor; Hepatitis B virus; Lamivudine; Living donor liver transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; STEROID; TACROLIMUS; VIRUS DNA;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CHOLANGIOGRAPHY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DNA DETERMINATION; DONOR SELECTION; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENDOSCOPY; ESOPHAGUS VARICES; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LIVING DONOR; POSTOPERATIVE PERIOD; RECURRENT INFECTION; REOPERATION; SPLENOMEGALY; TREATMENT RESPONSE;

FEMALE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; MIDDLE AGED;

EID: 35148875139     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01528.x     Document Type: Article

References (16)

1. Munoz SJ. Use of hepatitis C core antibody-positive donors for liver transplantation. Liver Transpl 2002; 8(Suppl. 1): S82-7.
2. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68: 1058-61.
3. Burton JR Jr, Shaw-Stiffel TA. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: A survey of current practice in the United States. Liver Transpl 2003; 9: 837-42.
4. Marusawa H, Osaki Y, Kimura T, et al. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut 1999; 45: 284-8.
5. Chen YS, Wang CC, de Villa VH, et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transpl 2002; 16: 405-9.
6. Chang SH, Suh KS, Yi NJ, et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003; 37: 1329-34.
7. Lo CM, Fan ST, Liu CL, et al. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl 2003; 9: 827-32.
8. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113: 1668-74.
9. Gonzalez-Peralta RP, Andres JM, Tung FY, et al. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient. Transplantation 1994; 15: 114-6.
10. Franchello A, Ghisetti V, Marzano A, Romagnoli R, Salizzoni M. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl 2005; 11: 922-8.
11. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769-74.
12. Picardi M, Pane F, Quintarelli C, et al. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003; 88: 1296-303.
13. Hui CK, Lie A, Au WY, et al. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transpl 2005; 5: 1437-45.
14. Myers RP, Swain MG, Urbanski SJ, Lee SS. Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol 2001; 15: 599-603.
15. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28: 1032-5.
16. Lueg E, Heathcote J. Dangers of immunosuppressive therapy in hepatitis B virus carriers. Can Med Assoc J 1992; 147: 1155-8.